Directs Cannabis Regulatory Commission to adopt regulations concerning labeling, marketing, and sale of cannabidiol and products containing cannabidiol; prohibits sale of cannabidiol to minors.
Impact
The law will have a major impact on state regulations concerning CBD products by imposing new health and safety standards. These include guidelines on dosage, potency limits, and comprehensive labeling requirements that will outline necessary product information such as the total amount of cannabidiol per serving and specific health claims permitted in advertisements. Additionally, the bill proposes penalties for violations of these regulations, which could lead to significant civil fines for businesses that sell CBD products to minors or mislabel their products.
Summary
Assembly Bill A1684 aims to regulate the marketing, labeling, and sale of cannabidiol (CBD) products within New Jersey. Specifically, it directs the Cannabis Regulatory Commission to adopt comprehensive regulations concerning various aspects of CBD products, including their labeling, marketing practices, and sales processes. A significant emphasis is placed on prohibiting the sale of CBD products to minors, with specific penalties established for violations. This move aims both to protect young individuals and to standardize the sale of CBD products across the state, ensuring that consumers have access to safe and properly marketed goods.
Contention
While supporters of the bill argue that it provides essential protections for consumers, particularly minors, opponents may contend that excessive regulation could stifle the burgeoning CBD market. Some stakeholders in the hemp industry might argue that these regulations may be too restrictive or complicate the operational landscape for small businesses looking to enter the market. The ongoing dialogue around this bill may reflect a broader tension between promoting public health and allowing for economic growth and innovation in the cannabis sector.
Directs Cannabis Regulatory Commission to adopt regulations concerning labeling, marketing, and sale of cannabidiol and products containing cannabidiol; prohibits sale of cannabidiol to minors.
Creating the Kansas medical cannabis act to authorize the cultivation, processing, distribution, sale and use of medical cannabis and medical cannabis products and the Kansas cannabidiol regulation act to regulate the testing and retail sale of cannabidiol products.
To provide for the regulation of industrial hemp, industrial hemp products, and industrial hemp-derived cannabidiol (CBD) products (EN INCREASE GF EX See Note)
Directs Cannabis Regulatory Commission to adopt regulations concerning labeling, marketing, and sale of cannabidiol and products containing cannabidiol; prohibits sale of cannabidiol to minors.
A bill for an act relating to marijuana, including the manufacture, delivery, and possession of marijuana, the licensure of retail marijuana, and medical cannabis, providing fees, including excise taxes, establishing funds, providing penalties, and including effective date provisions.
A bill for an act relating to the medical cannabidiol program including medical cannabidiol dispensaries and manufacturers, income tax deductions, and sales and use tax, and including retroactive applicability provisions.